403 related articles for article (PubMed ID: 30234904)
1. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
3. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
Lee WP; Datta BN; Ong BB; Rees A; Halcox J
Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lipid reduction with DALI and MONET.
Ramlow W; Röseler E; Heigl F; Spitthöver R; Ringel J; Schmitz G; Heinzler R; Abdul-Rahman N; Leistikow F; Himmelsbach F; Schettler V; Pham J; Kozik-Jaromin J
Atheroscler Suppl; 2017 Nov; 30():217-224. PubMed ID: 29096841
[TBL] [Abstract][Full Text] [Related]
8. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions.
Bosch T; Gahr S; Belschner U; Schaefer C; Lennertz A; Rammo J;
Ther Apher Dial; 2006 Jun; 10(3):210-8. PubMed ID: 16817783
[TBL] [Abstract][Full Text] [Related]
9. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
10. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
13. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
[TBL] [Abstract][Full Text] [Related]
14. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
Kayikcioglu M; Tokgozoglu L; Dogan V; Ceyhan C; Tuncez A; Kutlu M; Onrat E; Alici G; Akbulut M; Celik A; Yesilbursa D; Sahin T; Sonmez A; Ozdogan O; Temizhan A; Kilic S; Bayram F; Sabuncu T; Coskun FY; Ildizli M; Durakoglugil E; Kirilmaz B; Yilmaz MB; Yigit Z; Yildirim AB; Gedikli O; Topcu S; Oğuz A; Demir M; Yenerçağ M; Yıldırır A; Demircan S; Yilmaz M; Kaynar LG; Aktan M; Durmus RB; Gokce C; Ozcebe Oİ; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O; Can LH
Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
[TBL] [Abstract][Full Text] [Related]
15. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
16. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
Thiery J; Seidel D
Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein apheresis in the management of severe hypercholesterolemia and hyperlipoproteinemia(a)-The Portuguese experience.
Ferreira L; Palma I; Bacelar C; Queirós JA; Madureira A; Oliveira JC; Ramos MH; Cardoso H
Transfus Apher Sci; 2018 Oct; 57(5):676-680. PubMed ID: 30287070
[TBL] [Abstract][Full Text] [Related]
18. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Olbricht CJ; Schoeppe E
Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
[TBL] [Abstract][Full Text] [Related]
20. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
Dlouha D; Blaha M; Blaha V; Fatorova I; Hubacek JA; Stavek P; Lanska V; Parikova A; Pitha J
Atheroscler Suppl; 2017 Nov; 30():128-134. PubMed ID: 29096828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
